| Company: | DexCom |
|---|---|
| CEO: | Jacob Steven Leach |
| Symbol: | DXCM |
| Exchange: | NASDAQ |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| About |
DexCom is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom was founded in 1999 and maintains its headquarters in San Diego, California. |
57 among 2804 companies
6340 Sequence Drive
San Diego | CA |
US
| DexCom;DXCM;https://bullfincher.io/logos/us/DXCM.png;dexcom | 4662000000.00 |
|---|---|
| Stryker Corporation;SYK;https://bullfincher.io/logos/us/SYK.png;stryker-corporation | 25116000000.00 |
| Abbott Laboratories;ABT;https://bullfincher.io/logos/us/ABT.png;abbott-laboratories | 44328000000.00 |
| Boston Scientific Corporation;BSX;https://bullfincher.io/logos/us/BSX.png;boston-scientific-corporation | 20074000000.00 |
Jacob Steven Leach is the CEO of DexCom.
DexCom operates in the Medical - Devices industry and the Healthcare sector.
DexCom has 11,100 employees.
In fiscal year 2025, DexCom generated a revenue of $4.66 Billion.
In fiscal year 2025, DexCom reported a net income of $836.30 Million.
DexCom went public on Apr 14, 2005, through its Initial Public Offering (IPO), and it has been 21 years since then.
DexCom's ticker symbol is DXCM, and the company is listed on the NASDAQ stock market exchange.
DexCom's current stock price is $75.37 as of Jun 13, 2026.
Ranked #57among 2,804 companies based on market cap.
Competitors of DexCom include Stryker Corporation, Abbott Laboratories and Boston Scientific Corporation, and more.